Skip to main content
Premium Trial:

Request an Annual Quote

Beckman Coulter Posts Rise in Q2 Sales

NEW YORK, July 26 (GenomeWeb News) - Beckman Coulter reported today a roughly eight percent rise in second-quarter sales, driven in part by growth in the company's clinical diagnostics and biomedical research divisions.


Beckman Coulter's sales for the period were $597.3 million, up from $551.8 million in the second quarter 2003. Sales in the company's clinical diagnostics division climbed 10 percent on strong sales of the UniCel Dxl 800 immunoassay system, while sales in its biomedical division were up four percent.


Beckman Coulter posted net earnings of $58.3 million in the second quarter, an almost 12 percent increased over the $52.2 million recorded in same period last year.


Looking ahead, the company said that it expects sales in the third quarter to rise between eight and 11 percent, and total year sales to be up nine to 10 percent.


The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.